ALPN

Alpine Immune Sciences, Inc.

33.86 USD
-0.06 (-0.18%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Alpine Immune Sciences, Inc. stock is up 34.79% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 10 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
26 Jan 19:19 15 Mar, 2024 20.00 CALL 100 4
07 Feb 15:09 16 Feb, 2024 20.00 CALL 75 221
13 Feb 18:41 15 Mar, 2024 20.00 CALL 100 300
13 Feb 18:42 15 Mar, 2024 20.00 CALL 100 300
13 Feb 20:51 15 Mar, 2024 20.00 CALL 100 300
16 Feb 17:23 17 May, 2024 30.00 CALL 55 60
16 Feb 17:25 17 May, 2024 30.00 CALL 76 60
16 Feb 19:43 17 May, 2024 30.00 CALL 50 60
16 Feb 20:51 17 May, 2024 30.00 CALL 57 60
16 Feb 20:52 17 May, 2024 30.00 CALL 55 60

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the. treatment of autoimmune and inflammatory diseases.

  • Wolfe Research
    Thu Feb 15, 06:15
    buy
    initial
  • Wedbush
    Fri Jan 26, 08:32
    buy
    confirm